<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

2 min read

Gene Therapies for Rare Disorders, March 26-29

Gene Therapies for Rare Disorders, March 26-29

Date: March 26-29, 2024

Location: Westin Copley Place Boston - Get directions

Event website: https://genetherapy-conference.com/ 

 

Join us for our presentation & MEET OUR TEAM!

Don't miss our speaker on March 28 from 11:45am - 12:15pm. Monika Pema, Sr. Manager of Process Validation, will be presenting as part of the manufacturing track on "Navigating Complexities of LV Vector from Clinical to Commercial Production: Lesson Learnings". We hope to see you there!

Would you like to talk with one of our team members? Interested in learning more about our global network and capabilities? Click the button below or email one of our attending representatives at the event to set up a meeting.

REQUEST A MEETING

You can also reach out directly to our experts attending the show

Monika Pema
Sr. Manager, Process Validation
Email  me
Raghu Malapaka, PhD
Sr. Director, Business Development
Email  me
Paul DiCandeloro
Sr. Director, Business Development
Email  me

Explore our AAV & LVV Platforms

BravoAAV™ and ProntoLVV™ are end-to-end platforms offering a proprietary GOI backbone and plug-and-play templates for any project. Our services include proprietary plasmids, in-house analytical panels, master cell banks, pre-qualified processes and fill and finish services.  

Our new templated adeno-associated viral vector platform.

 Learn about Bravo

Our new templated lentiviral vector platform.
 

Learn about our cell and gene therapy services 

Cell Therapy Production and Manufacturing

AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.  

Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting. 

Cell therapy offering 

 

Plasmid DNA (pDNA) Materials 

To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing. 

Plasmid offering

 

Viral Vector Production and Manufacturing 

AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products. 

Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house. 

Viral vector services 

 

Fill out the form below to request a meeting during the event

 

Bio Korea 2024, May 8-10

Bio Korea 2024, May 8-10

CPHI North America, May 7-9

CPHI North America, May 7-9

ASGCT Annual Meeting, May 7-11

ASGCT Annual Meeting, May 7-11